Foresight Diagnostics and Roche Resolve Patent Dispute with PhasED-Seq Licensing Agreement for Non-Hodgkin's Lymphoma Diagnostics
Key Insights
Foresight Diagnostics (search) and Roche have entered a limited licensing agreement for PhasED-Seq (search) technology, resolving litigation between the parties with all claims dismissed with prejudice.
Roche receives a non-exclusive, royalty-bearing sublicense to develop in vitro diagnostic kits for Non-Hodgkin's Lymphoma (search) using the PhasED-Seq (search) platform.
The PhasED-Seq (search) technology demonstrates superior sensitivity in detecting circulating tumor DNA (search) at 0.0001% compared to existing methods, potentially enhancing minimal residual disease monitoring.
Foresight Diagnostics (search) announced in August 2025 that it has entered into a limited licensing agreement with Roche Molecular Systems and Roche Sequencing Systems for its patented PhasED-Seq (search)™ technology, effectively closing litigation between the parties. Under the agreement, all claims against Foresight, its founders, and Stanford University have been dismissed with prejudice.
Licensing Terms and Structure
The agreement grants Roche a limited royalty-bearing non-exclusive sublicense under certain patents for use of PhasED-Seq (search) in developing in vitro diagnostic (IVD) kits specifically for Non-Hodgkin's Lymphoma (search) (NHL). Intellectual property rights in the PhasED-Seq technology remain with Stanford University, with Foresight continuing to hold the exclusive license to the patents for all uses and geographies outside of this specific arrangement.
"We are pleased to have resolved our differences with Roche and to move forward with this licensing agreement, which provides Roche with tailored rights in the field of Non-Hodgkin's Lymphoma (search)," said Jake Chabon, PhD, Chief Executive Officer of Foresight Diagnostics (search). "This resolution allows Foresight to remain focused on our mission to advance cutting-edge diagnostics aimed at improving outcomes for cancer patients worldwide."
Technology Advantages and Clinical Applications
The PhasED-Seq (search) platform represents a significant advancement in minimal residual disease (MRD) detection capabilities. The technology lowers the error profile of mutation detection in sequencing data by requiring the concordant detection of two separate non-reference events in an individual DNA molecule. By detecting more than one mutation, PhasED-Seq can more accurately distinguish tumor-derived cell free DNA (ctDNA (search)) from healthy cell free DNA.
This enhanced approach enables detection of ctDNA (search) at levels below one part-per-million (<0.0001%), demonstrating superior sensitivity compared to existing methods that typically detect at 0.01% levels. The technology has been extensively tested in thousands of patient samples, providing substantial validation for its clinical utility.
Legal Resolution and Market Implications
The legal dispute centered on allegations that PhasED-Seq (search) was derived from Roche's CAPP-Seq (search) trade secrets, with Roche arguing that Stanford professors Maximilian Diehn and Ash Alizadeh, who founded Foresight, misappropriated proprietary data during their tenure as Roche consultants. Foresight countered that PhasED-Seq was independently developed using Stanford resources and that CAPP-Seq's core methods had already been publicly disclosed.
The resolution allows Roche to enhance its diagnostic portfolio in NHL, a heterogeneous group of blood cancers that requires precise biomarker identification to guide treatment. For Foresight, the agreement provides a revenue stream while maintaining broad commercial control over the technology for other applications.
Market Context and Growth Potential
The agreement occurs within a rapidly expanding precision medicine market, with the global clinical oncology next-generation sequencing market projected to grow at a 20.3% CAGR from 2025 to 2030. The NGS-based RNA-sequencing market is forecasted to expand from $4.25 billion in 2024 to $21.32 billion by 2034, driven by advancements in single-cell resolution and AI-powered data analysis.
Roche's AVENIO MRD monitoring portfolio generated $420 million in annual revenue in 2025, positioning the company to leverage PhasED-Seq (search)'s enhanced sensitivity for improved NHL diagnostic capabilities. The licensing structure reflects the growing importance of royalty-based models in precision medicine, where companies prioritize scalable, recurring revenue streams over one-time licensing fees.